NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

CompletedPhase 4

Sponsor: The University of Hong Kong

Conditions: COVID 19 Vaccine

Interventions: BNT162b2

Countries: Hong Kong

300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech). Investigators will monitor reactogenicity and measure the immune response to the third dose.

Eligibility overview

Sex: ALL

Age: 30 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Aged 30 years or older at enrolment.
* Have received two doses of any inactivated COVID-19 vaccines (for example Sinovac- CoronaVac, Sinopharm-BIBP) with the most recent dose at least 90 days prior to enrolment.
* Currently resident and planning to remain resident in Hong Kong during the duration of the study, i.e. for 12 months after enrolment.
* Agreement to refrain from blood donation during the course of the study.
* Willing to provide blood samples for all the required time points.
* The individual or their caregiver have a home phone or cellular or mobile phone for communications purpose.
* Capable of providing informed consent.

Exclusion Criteria:

* A history of laboratory-confirmed or clinically confirmed COVID-19 infection. Have received (at least one dose of) any COVID-19 vaccines other than inactivated vaccines.
* Individuals who report any medical condition, or as determined by a clinician, not suitable to receive mRNA vaccines, including but not limited to allergies to the active substance or other ingredients of the vaccine.
* With diagnosed medical conditions related to their immune system.
* Use of medication that impairs immune system in the last 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days).
* Have used immunoglobulins and/or any blood products within 90 days prior to enrolment (administration of the study vaccine).
* Pregnancy, lactation or intention to become pregnant in the coming 3 months.

Locations (1)

Hong Kong, Hong Kong